Emerging drugs to target lower urinary tract symptomatology (LUTS)/benign prostatic hyperplasia (BPH): focus on the prostate.
Benign prostatic hyperplasia (BPH)
Lower urinary tract symptoms (LUTS)
Pharmacotherapy
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
14
01
2019
accepted:
28
08
2019
pubmed:
12
9
2019
medline:
26
2
2021
entrez:
12
9
2019
Statut:
ppublish
Résumé
The benign prostatic syndrome, comprising lower urinary tract symptomatology secondary to benign prostatic hyperplasia/enlargement, represents a major health care issue in westernized countries. The pharmacological management involves alpha-adrenoceptor antagonists, intervention into the hormonal control of prostate growth using inhibitors of the enzyme 5-alpha-reductase, and stimulation of the nitric oxide/cyclic GMP pathway by tadalafil, an inhibitor of the phosphodiesterase type 5. This review summarizes the achievements which have been made in the development of drug candidates assumed to offer opportunities as beneficial treatment options in the management of the benign prostatic syndrome. A review of the literature has revealed that the line of development is focusing on drugs interfering with peripheral neuromuscular/neuronal mechanisms (nitric oxide donor drugs, agonists/antagonists of endogenous peptides, botulinum toxin, NX-1207), the steroidal axis (cetrorelix) or the metabolic turn-over (lonidamine), as well as the combination of drugs already established in the treatment of lower urinary tract symptomatology/benign prostatic hyperplasia (phosphodiesterase 5 inhibitor plus alpha-adrenoceptor antagonist). Many research efforts have provided the basis for the development of new therapeutic modalities for the management of lower urinary tract dysfunctions, some of which might be offered to the patients in the near future.
Identifiants
pubmed: 31506747
doi: 10.1007/s00345-019-02933-1
pii: 10.1007/s00345-019-02933-1
doi:
Substances chimiques
Adrenergic alpha-Antagonists
0
Nitric Oxide
31C4KY9ESH
Botulinum Toxins
EC 3.4.24.69
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1423-1435Références
Guess HA (1995) Epidemiology and natural history of benign prostatic hyperplasia. Urol Clin North Am 22:247–261
pubmed: 7539173
Paolone DR (2010) Benign prostatic hyperplasia. Clin Geriatr Med 26:223–239
pubmed: 20497842
doi: 10.1016/j.cger.2010.02.010
Chughtai B, Forde JC, Thomas DD, Laor L, Hossack T, Woo HH, Te AE, Kaplan SA (2016) Benign prostatic hyperplasia. Nat Rev Dis Primers 2:16031
pubmed: 27147135
doi: 10.1038/nrdp.2016.31
Andersson KE (2002) Alpha-adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with alpha-adrenoceptor antagonists. World J Urol 19:390–396
pubmed: 12022707
doi: 10.1007/s00345-001-0237-0
Djavan B, Chapple C, Milani S, Marberger M (2004) State of the art on the efficacy and tolerability of alpha
pubmed: 15596173
doi: 10.1016/j.urology.2004.07.031
Lepor H (2016) Alpha-blockers for the treatment of benign prostatic hyperplasia. Urol Clin North Am 43:311–323
pubmed: 27476124
doi: 10.1016/j.ucl.2016.04.009
Roehrborn CG, Schwinn DA (2004) Alpha
pubmed: 14767264
doi: 10.1097/01.ju.0000097026.43866.cc
van Kerrebroeck P, Chapple C, Drogendijk T, Klaver M, Sokol R, Speakman M, Traudtner K, Drake MJ (for the NEPTUNE Study Group) (2013) Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. Eur Urol 64:1003–1012
doi: 10.1016/j.eururo.2013.07.034
Drake MJ, Oelke M, Snijder R, Klaver M, Traudtner K, van Charldorp K, Bongaerts D, van Kerrebroeck P (2017) Incidence of urinary retention during treatment with singe tablet combinations of solifenacin + tamsulosin OCAS™ for up to 1 year in adult men with both storage and voiding LUTS: a subanalysis of the NEPTUNE/NEPTUNE II randomized controlled studies. PLoS One 12:e0170726
pubmed: 28166296
pmcid: 5293258
doi: 10.1371/journal.pone.0170726
Naslund MJ, Miner M (2007) A review of the clinical efficacy and safety of 5-alpha-reductase inhibitors for the enlarged prostate. Clin Ther 29:17–25
pubmed: 17379044
doi: 10.1016/j.clinthera.2007.01.018
Nickel JC, Gilling P, Tammela TL, Morrill B, Wilson TH, Rittmaster RS (2011) Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU Int 108:388–394
pubmed: 21631695
doi: 10.1111/j.1464-410X.2011.10195.x
Roehrborn CG, Oyarzabal Perez I, Roos EP, Calomfirescu N, Brotherton B, Wang F, Palacios JM, Vasylyev A, Manyak MJ (2015) Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (DUODART) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naïve men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results. BJU Int 16:450–459
doi: 10.1111/bju.13033
de Nunzio C, Presicce F, Tubaro A (2016) Combination therapies for improved management of lower urinary tract symptoms/benign prostatic hyperplasia. Drugs Today (Barcelona) 52:501–517
doi: 10.1358/dot.2016.52.9.2525739
Ozdemir I, Bozkurt O, Demir O, Aslan G, Esen AA (2009) Combination therapy with doxazosin and tenoxicam for the management of lower urinary tract symptoms. Urology 74:431–435
pubmed: 19501883
doi: 10.1016/j.urology.2009.01.088
Porst H, Kim ED, CasabE AR et al (2011) Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial. Eur Urol 60:1105–1113
pubmed: 21871706
doi: 10.1016/j.eururo.2011.08.005
Porst H, Oelke M, Goldfischer ER, Cox D, Watts S, Dey D, Viktrup L (2013) Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multi-national, randomized, placebo-controlled clinical studies. Urology 82:667–673
pubmed: 23876588
doi: 10.1016/j.urology.2013.05.005
Dmochowski R, Roehrborn C, Klise S, Xu L, Kaminetsky J, Kraus S (2013) Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial. J Urol 189(Suppl 1):S135–S140
pubmed: 23234619
Dedhia RC, McVary KT (2008) Phytotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 179:2119–2125
pubmed: 18423748
doi: 10.1016/j.juro.2008.01.094
Sharma M, Chadha R, Dhingra N (2017) Phytotherapeutic agents for benign prostatic hyperplasia: an overview. Mini Rev Med Chem 17:1346–1363
pubmed: 27337973
de Mey C (1998) Cardiovascular effects of alpha-blockers used for the treatment of symptomatic BPH: impact on safety and well-being. Eur Urol 34(Suppl 2):18–28 (Erratum in: Eur Urol (1998) 34:527)
pubmed: 9732829
doi: 10.1159/000052284
Castiglione F, Benigni F, Briganti A, Salonia A, Villa L, Nini A, Di Trapani E, Capitanio U, Hedlund P, Montorsi F (2014) Naftopidil for the treatment of benign prostate hyperplasia: a systematic review. Curr Med Res Opin 30:719–732
pubmed: 24188134
doi: 10.1185/03007995.2013.861813
Perumal C, Chowdhury PS, Ananthakrishnan N, Nayak P, Gurumurthy S (2015) A comparison of the efficacy of naftopidil and tamsulosin hydrochloride in medical treatment of benign prostatic enlargement. Urol Ann 7:74–78
pubmed: 25657550
pmcid: 4310123
doi: 10.4103/0974-7796.148624
Tsuritani S, Nozaki T, Okumura A, Kimura H, Kazama T (2010) A prospective, randomized, controlled, multicenter study of naftopidil for treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: 75 mg once daily in the evening compared to 25 mg thrice daily. Urol Int 85:80–87
pubmed: 20516676
doi: 10.1159/000315994
Yokoyama T, Kumon H, Nasu Y, Takamoto H, Watanabe T (2006) Comparison of 25 and 75 mg/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective, randomized controlled study. Int J Urol 13:932–938
pubmed: 16882058
doi: 10.1111/j.1442-2042.2006.01443.x
Yasuda K, Yamanishi T, Tojo M, Nagashima K, Akimoto S, Shimazaki J (1994) Effect of naftopidil on urethral obstruction in benign prostatic hyperplasia: assessment by urodynamic studies. Prostate 25:46–52
pubmed: 7517541
doi: 10.1002/pros.2990250107
Tanaka T, Kuratsukuri K, Yoshimura R, Adachi T, Yamaguchi T, Ohmachi T, Yamamoto S, Nakamura T, Tamada S, Nakatani T (2015) Efficacy of naftopidil for nocturia in male patients with lower urinary tract symptoms: comparison of morning and evening dosing. Int J Urol 22:317–321
pubmed: 25421868
doi: 10.1111/iju.12669
Chang RS, Chen TB, O’Malley SS, Pettibone DJ, DiSalvo J, Francis B, Bock MG, Freidinger R, Nagarathnam D, Miao SW, Shen Q, Lagu B, Murali Dhar TG, Tyagarajan S, Marzabadi MR, Wong WC, Gluchowski C, Forray C (2000) In vitro studies on L-771.688 (SNAP 6383), a new potent and selective alpha
pubmed: 11108825
doi: 10.1016/S0014-2999(00)00854-2
Ford AP, Arredondo NF, Blue DR Jr, Bonhaus DW, Jasper J, Kava MS, Lesnick J, Pfister JR, Shieh IA, Vimont RL, Williams TJ, McNeal JE, Stamey TA, Clarke DE (1996) RS-17053 (N-[2-(2-cyclopropyl-methoxyphenoxy)ethyl]-5-chloro-alpha, alpha-dimethyl-1H-indole-3-ethanamine hydrochloride), a selective alpha
pubmed: 8632751
Marshall I, Burt RP, Green GM, Hussain MB, Chapple CR (1996) Different subtypes of alpha
pubmed: 8886428
pmcid: 1915842
doi: 10.1111/j.1476-5381.1996.tb16001.x
Hedlund P, Ekstrom P, Larsson B, Alm P, Andersson KE (1997) Heme oxygenase and NO-synthase in the human prostate—relation to adrenergic, cholinergic and peptide-containing nerves. J Auton Nerv Syst 63:115–126
pubmed: 9138243
doi: 10.1016/S0165-1838(96)00139-7
Hedlund P, Larsson B, Alm P, Andersson KE (1996) Nitric oxide synthase-containing nerves and ganglia in the dog prostate: a comparison with other transmitters. Histochem J 28:635–642
pubmed: 8910034
doi: 10.1007/BF02331384
Takeda M, Tang R, Shapiro E, Burnett AL, Lepor H (1995) Effects of nitric oxide on human and canine prostates. Urology 45:440–446
pubmed: 7879335
doi: 10.1016/S0090-4295(99)80013-2
Naibar-Kaszkiel AT, Di Iulio JL, Li CG, Rand MJ (1997) Characterisation of excitatory and inhibitory transmitter systems in prostate glands of rats, guinea pigs, rabbits and pigs. Eur J Pharmacol 337:251–258
doi: 10.1016/S0014-2999(97)01270-3
Hennenberg M, Schott M, Kan A, Keller P, Tamalunas A, Ciotkowska A, Rutz B, Wang Y, Strittmatter F, Herlemann A, Yu Q, Stief CG, Gratzke C (2016) Inhibition of adrenergic and non-adrenergic smooth muscle contraction in the human prostate by the phosphodiesterase 10-selective inhibitor TC-E 5005. Prostate 76:1364–1374
pubmed: 27418235
doi: 10.1002/pros.23208
Bechara A, Romano S, Casabé A, Haime S, Dedola P, Hernández C, Rey H (2008) Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. J Sex Med 5:2170–2178
pubmed: 18638006
doi: 10.1111/j.1743-6109.2008.00940.x
Kim SW, Park NC, Lee SW, Yang DY, Park JK, Moon DG, Yang SK, Lee SW, Moon KH, Ahn TY, Kim SW, Park K, Min KS, Ryu JK, Son H, Jung J, Hyun JS (2017) Efficacy and safety of a fixed-dose combination therapy of tamsulosin and tadalafil for patients with lower urinary tract symptoms and erectile dysfunction: results of a randomized, double-blinded, active-controlled trial. J Sex Med 14:1018–1027
pubmed: 28760246
doi: 10.1016/j.jsxm.2017.06.006
Kaplan SA, Gonzalez RR, Te AE (2007) Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 51:1717–1723
pubmed: 17258855
doi: 10.1016/j.eururo.2007.01.033
Fawzi A, Kamel M, Salem E, Desoky E, Omran M, Elgalaly H, Sakr A, Maarouf A, Khalil S (2016) Sildenafil citrate in combination with tamsulosin versus tamsulosin monotherapy for management of male lower urinary tract symptoms due to benign prostatic hyperplasia: a randomised, double-blind, placebo-controlled trial. Arab J Urol 15:53–59
pubmed: 28275519
pmcid: 5329701
doi: 10.1016/j.aju.2016.11.001
Gacci M, Vittori G, Tosi N, Siena G, Rossetti MA, Lapini A, Vignozzi L, Serni S, Maggi M, Carini M (2012) A randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Sex Med 9:1624–1633
pubmed: 22510238
doi: 10.1111/j.1743-6109.2012.02718.x
Mason RP, Cockcroft JR (2006) Targeting nitric oxide with drug therapy. J Clin Hypertens (Greenwich) 8(Suppl 4):40–52
doi: 10.1111/j.1524-6175.2006.06041.x
Scatena R, Bottoni P, Martorana GE, Giardina B (2005) Nitric oxide donor drugs: an update on pathophysiology and therapeutic potential. Expert Opin Investig Drugs 14:835–846
pubmed: 16022573
doi: 10.1517/13543784.14.7.835
Oliveira-Paula GH, Tanus-Santos JE (2019) Nitrite-stimulated gastric formation of S-nitrosothiols as an antihypertensive therapeutic strategy. Curr Drug Targets 20:431–443
pubmed: 30112990
doi: 10.2174/1389450119666180816120816
Kedia GT, Ückert S, Kedia M, Truss MC, Chigogidze T, Jonas U, Managadze LG (2006) In vitro effects of cyclic AMP- and cyclic GMP-stimulating drugs on the relaxation of the prostate smooth muscle tissue contraction induced by endothelin-1. Georgian Med News 131:7–13
Kedia GT, Ückert S, Scheller F, Chigogidze T, Managadze L, Jonas U, Truss MC (2006) In vitro functional responses of isolated normal human prostatic tissue to compounds interacting with the cyclic guanosine monophosphate pathway. Urology 67:1292–1297
pubmed: 16678889
doi: 10.1016/j.urology.2005.12.002
Heuer O, Ückert S, Dobler G, Klocker H, Stief CG, Truss MC, Bartsch G, Jonas U (2004) Effects of phosphodiesterase inhibitors and nitric oxide donors on cultured human prostatic smooth muscle cells. Eur Urol 3(Suppl 2):19 (Abstract, presented at the 19th Congress of the European Association of Urology (EAU), Vienna, Austria, 24-March to 27-March 2004)
doi: 10.1016/S1569-9056(04)90068-1
Berger AP, Deibl M, Leonhartsberger N, Bektic J, Horninger W, Fritsche G, Steiner H, Pelzer AE, Bartsch G, Frauscher F (2005) Vascular damage as a risk factor for benign prostatic hyperplasia and erectile dysfunction. BJU Int 96:1073–1078
pubmed: 16225531
doi: 10.1111/j.1464-410X.2005.05777.x
Saito M, Tsounapi P, Oikawa R, Shimizu S, Honda M, Sejima T, Kinoshita Y, Tomita S (2014) Prostatic ischemia induces ventral prostatic hyperplasia in the SHR: possible mechanism of development of BPH. Sci Rep 4:3822
pubmed: 24448152
pmcid: 3897960
doi: 10.1038/srep03822
Fernandes VS, Martínez-Sáenz A, Recio P, Ribeiro AS, Sánchez A, Martínez MP, Martínez AC, García-Sacristán A, Orensanz LM, Prieto D, Hernández M (2011) Mechanisms involved in nitric oxide-induced vasorelaxation in porcine prostatic arteries. Naunyn Schmiedebergs Arch Pharmacol 384:245–253
pubmed: 21748357
doi: 10.1007/s00210-011-0666-2
Roshani A, Khosropanah I, Salehi M, Kamran AN (2010) Effects of isosorbide dinitrate on the urinary flow rate in patients with benign prostatic hyperplasia. Urol J 7:183–187
pubmed: 20845295
Tadayyon F, Izadpanahi M, Aali S, Mazdak H, Khorrami MH (2012) The effect of sublingual isosorbide dinitrate on acute urinary retention due to benign prostatic hyperplasia. Saudi J Kidney Dis Transpl 23:782–785
pubmed: 22805391
doi: 10.4103/1319-2442.98160
Klotz T, Mathers MJ, Bloch W, Nayal W, Engelmann U (1999) Nitric oxide based influence of nitrates on micturition in patients with benign prostatic hyperplasia. Int Urol Nephrol 31:335–341
pubmed: 10672953
doi: 10.1023/A:1007174102953
Hedlund P (2005) Nitric oxide/cGMP-mediated effects in the outflow region of the lower urinary tract—is there a basis for pharmacological targeting of cGMP? World J Urol 23:362–367
pubmed: 16283327
doi: 10.1007/s00345-005-0019-1
Kedia GT, Ückert S, Jonas U, Kuczyk MA, Burchardt M (2008) The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms. World J Urol 26:603–609
pubmed: 18607596
doi: 10.1007/s00345-008-0303-y
Siejka A, Schally AV, Block NL, Barabutis N (2010) Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix. BJU Int 106:1382–1388
pubmed: 20151966
doi: 10.1111/j.1464-410X.2010.09215.x
Rozsa B, Nadji M, Schally AV, Dezso B, Flasko T, Toth G, Mile M, Block NL, Halmos G (2011) Receptors for luteinizing hormone-releasing hormone (LHRH) in benign prostatic hyperplasia (BPH) as potential molecular targets for therapy with LHRH antagonist cetrorelix. Prostate 71:445–452
pubmed: 20859992
doi: 10.1002/pros.21258
Rick FG, Schally AV, Block NL, Halmos G, Perez R, Fernandez JB, Vidaurre I, Szalontay L (2001) LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia. Prostate 71:736–747
doi: 10.1002/pros.21289
Debruyne F, Tzvetkov M, Altarac S, Geavlete PA (2010) Dose-ranging study of the luteinizing hormone-releasing hormone receptor antagonist cetrorelixpamoate in the treatment of patients with symptomatic benign prostatic hyperplasia. Urology 76:927–933
pubmed: 20932411
doi: 10.1016/j.urology.2009.09.077
Swaminathan S (2011) Molecular structures and functional relationships in clostridial neurotoxins. FEBS J 278:4467–4485
pubmed: 21592305
doi: 10.1111/j.1742-4658.2011.08183.x
Lam KH, Yao G, Jin R (2015) Diverse binding modes, same goal: the receptor recognition mechanism of botulinum neurotoxin. Prog Biophys Mol Biol 117:225–231
pubmed: 25701633
pmcid: 4417461
doi: 10.1016/j.pbiomolbio.2015.02.004
Chartier-Kastler E, Mehnert U, Denys P, Giuliano F (2009) Perspective of Botox for treatment of male lower urinary tract symptoms. Curr Opin Urol 19:20–25
doi: 10.1097/MOU.0b013e328316c33f
Brisinda G, Cadeddu F, Vanella S, Mazzeo P, Marniga G, Maria G (2009) Relief by botulinum toxin of lower urinary tract symptoms owing to benign prostatic hyperplasia: early and long-term results. Urology 73:90–94
pubmed: 18995889
doi: 10.1016/j.urology.2008.08.475
Chuang YC, Chiang PH, Yoshimura N, De Miguel F, Chancellor MB (2006) Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia. BJU Int 98:1033–1037
pubmed: 16956361
doi: 10.1111/j.1464-410X.2006.06479.x
Sacco E, Bientinesi R, Marangi F, Totaro A, D’Addessi A, Racioppi M, Pinto F, Vittori M, Bassi P (2012) Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic onabotulinumtoxin A: 3 month results of a prospective single-armed cohort study. BJU Int 110(11):E837–E844
pubmed: 22712582
doi: 10.1111/j.1464-410X.2012.11288.x
Marberger M, Chartier-Kastler E, Egerdie B, Lee KS, Grosse J, Bugarin D, Zhou J, Patel A, Haag-Molkenteller C (2013) A randomized double-blind, placebo-controlled phase 2 dose-ranging study of onabotulinumtoxin A in men with benign prostatic hyperplasia. Eur Urol 63:496–503
pubmed: 23098762
doi: 10.1016/j.eururo.2012.10.005
Shim SR, Cho YJ, Shin IS, Kim JH (2016) Efficacy and safety of botulinum toxin injection for benign prostatic hyperplasia: a systematic review and meta-analysis. Int Urol Nephrol 48:19–30
pubmed: 26560471
doi: 10.1007/s11255-015-1153-3
Comeglio P, Chavalmane AK, Fibbi B, Filippi S, Marchetta M, Marini M, Morelli A, Penna G, Vignozzi L, Vannelli GB, Adorini L, Maggi M (2010) Human prostatic urethra expresses vitamin D receptor and responds to vitamin D receptor ligation. J Endocrinol Invest 33:730–738
pubmed: 20386089
doi: 10.1007/BF03346679
Morelli A, Vignozzi L, Filippi S, Vannelli GB, Ambrosini S, Mancina R, Crescioli C, Donati S, Fibbi B, Colli E, Adorini L, Maggi M (2007) BXL-628, a vitamin D receptor agonist effective in benign prostatic hyperplasia treatment, prevents RhoA activation and inhibits RhoA/Rho kinase signaling in rat and human bladder. Prostate 67:234–247
pubmed: 17163492
doi: 10.1002/pros.20463
Penna G, Fibbi B, Amuchastegui S, Corsiero E, Laverny G, Silvestrini E, Chavalmane A, Morelli A, Sarchielli E, Vannelli GB, Gacci M, Colli E, Maggi M, Adorini L (2009) The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappa B pathways. Prostate 69:480–493
pubmed: 19107880
doi: 10.1002/pros.20896
Adorini L, Penna G, Amuchastegui S, Cossetti C, Aquilano F, Mariani R, Fibbi B, Morelli A, Uskokovic M, Colli E, Maggi M (2007) Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol). J Steroid Biochem Mol Biol 103:689–693
pubmed: 17241782
doi: 10.1016/j.jsbmb.2006.12.065
Colli E, Rigatti P, Montorsi F, Artibani W, Petta S, Mondaini N, Scarpa R, Usai P, Olivieri L, Maggi M (for the BPH Italian Study Group) (2006) BXL-628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial. Eur Urol 49:82–86
doi: 10.1016/j.eururo.2005.08.014
Hanley MR, Benton HP, Lightman SL, Todd K, Bone EA, Fretten P, Palmer S, Kirk CJ, Michell RH (1984) A vasopressin-like peptide in the mammalian sympathetic nervous system. Nature (London) 309:258–261
doi: 10.1038/309258a0
van Kerrebroeck P (2011) Nocturia: current status and future perspectives. Curr Opin Obstet Gynecol 23:376–385
pubmed: 21897234
Oelke M, Adler E, Marschall-Kehrel D, Herrmann TR, Berges R (2014) Nocturia: state of the art and critical analysis of current assessment and treatment strategies. World J Urol 32:1109–1117
pubmed: 25216925
doi: 10.1007/s00345-014-1396-0
Ali F, Guglin M, Vaitkevicius P, Ghali JK (2007) Therapeutic potential of vasopressin receptor antagonists. Drugs 67:847–858
pubmed: 17428103
doi: 10.2165/00003495-200767060-00002
Lemmens-Gruber R, Kamyar M (2008) Pharmacology and clinical relevance of vasopressin antagonists. Der Internist (Berlin) 49:628–634
doi: 10.1007/s00108-008-2017-z
Yoshimura N, Kaiho Y, Miyazato M, Yunoki T, Tai C, Chancellor MB, Tyagi P (2008) Therapeutic receptor targets for lower urinary tract dysfunction. Naunyn Schmiedeberg’s Arch Pharmacol 377(4–6):437–448
doi: 10.1007/s00210-007-0209-z
Bodanszky M, Sharaf H, Roy JB, Said SI (1992) Contractile activity of vasotocin, oxytocin, and vasopressin on mammalian prostate. Eur J Pharmacol 216:311–313
pubmed: 1397015
doi: 10.1016/0014-2999(92)90376-F
Crankshaw D (1989) [Arg8]vasopressin-induced contractions of rabbit urinary bladder smooth muscle. Eur J Pharmacol 173(2–3):183–188
pubmed: 2625135
doi: 10.1016/0014-2999(89)90517-7
Gupta J, Russell R, Wayman C, Hurley D, Jackson V (2008) Oxytocin-induced contractions within rat and rabbit ejaculatory tissues are mediated by vasopressin V1A receptors and not oxytocin receptors. Br J Pharmacol 155:118–126
pubmed: 18552879
pmcid: 2527840
doi: 10.1038/bjp.2008.226
Palea S, Corsi M, Artibani W, Ostardo E, Pietra C (1996) Pharmacological characterization of tachykinin NK2 receptors on isolated human urinary bladder, prostatic urethra and prostate. J Pharmacol Exp Ther 277:700–705
pubmed: 8627548
Malherbe P, Ballard TM, Ratni H (2011) Tachykinin neurokinin 3 receptor antagonists: a patent review (2005–2010). Expert Opin Ther Pat 21:637–655
pubmed: 21417773
doi: 10.1517/13543776.2011.568482
Bakali E, Elliott RA, Taylor AH, Willets J, Konje JC, Tincello DG (2013) Distribution and function of the endocannabinoid system in the rat and human bladder. Int Urogynecol J 24:855–863
pubmed: 23081739
doi: 10.1007/s00192-012-1954-1
Hedlund P (2014) Cannabinoids and the endocannabinoid system in lower urinary tract function and dysfunction. Neurourol Urodyn 33:46–53
pubmed: 24285567
doi: 10.1002/nau.22442
Hedlund P, Gratzke C (2016) The endocannabinoid system—a target for the treatment of LUTS? Nat Rev Urol 13:463–470
pubmed: 27377161
doi: 10.1038/nrurol.2016.110
Gratzke C, Weinhold P, Reich O, Seitz M, Schlenker B, Stief CG, Andersson KE, Hedlund P (2010) Transient receptor potential A1 and cannabinoid receptor activity in human normal and hyperplastic prostate: relation to nerves and interstitial cells. Eur Urol 57:902–910
pubmed: 19733001
doi: 10.1016/j.eururo.2009.08.019
Shore N (2010) NX-1207: a novel investigational drug for the treatment of benign prostatic hyperplasia. Expert Opin Investig Drugs 19:305–310
pubmed: 20050813
doi: 10.1517/13543780903555196
Shore N, Cowan B (2011) The potential for NX-1207 in benign prostatic hyperplasia: an update for clinicians. Ther Adv Chronic Dis 2:283–377
doi: 10.1177/2040622311423128
Kunit T, Lusuardi L (2014) An evidence-based review of NX1207 and its potential in the treatment of benign prostatic hyperplasia. Res Rep Urol 6:67–70
pubmed: 25157337
pmcid: 4103918
Shore N, Tutrone R, Efros M, Bidair M, Wachs B, Kalota S, Freedman S, Bailen J, Levin R, Richardson S, Kaminetsky J, Snyder J, Shepard B, Goldberg K, Hay A, Gange S, Grunberger I (2018) Fexapotide triflutate: results of long-term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement. World J Urol 36:801–809
pubmed: 29380128
pmcid: 5916987
doi: 10.1007/s00345-018-2185-y
Brawer MK (2005) Lonidamine: basic science and rationale for treatment of prostatic proliferative disorders. Rev Urol 7(Suppl 7):S21–S526
pubmed: 16986057
pmcid: 1477623
Nath K, Guo L, Nancolas B, Nelson DS, Shestov AA, Lee SC, Roman J, Zhou R, Leeper DB, Halestrap AP, Blair IA, Glickson JD (2016) Mechanism of anti-neoplastic activity of lonidamine. Biochim Biophys Acta 1866:151–162
pubmed: 27497601
pmcid: 5138080
Roehrborn CG (2005) The development of lonidamine for benign prostatic hyperplasia and other indications. Rev Urol 7(Suppl 7):S12–S620
pubmed: 16986056
pmcid: 1477628
Ditonno P, Battaglia M, Selvaggio O, Garofalo L, Lorusso V, Selvaggi FP (2005) Clinical evidence supporting the role of lonidamine for the treatment of BPH. Rev Urol 7(Suppl 7):S27–S533
pubmed: 16986058
pmcid: 1477627